Furthermore, NEK4 knockdown caused the decreased expression of the transcriptional factor Zeb1 and Smads proteins, which are known to play key roles in EMT regulation. Consistently, overexpression of NEK4 resulted in the decreased expression of E-cadherin and increased expression of Smad3. Using a mouse model with tail vein injection of NEK4 knockdown stable cell line, we found a lower rate of tumor formation and metastasis of the NEK4-knockdown cells in vivo. Thus, this study demonstrates NEK4 as a novel kinase involved in regulation of EMT and suggests that NEK4 may be further explored as a potential therapeutic target for lung cancer metastasis.
system. In view of these findings, multiple strategies have been designed to interfere with EMT to identify potential therapeutic targets for cancer treatment, by reversing EMT to MET phenotype and reducing the drug-resistance. 8 Studies have suggested that EMT is a complexed and well-coordinated process, in which the extracellular signal molecules, transcription factors, miRNAs, epigenetic and posttranslational regulation all play critical roles. 9, 10 The transforming growth factor-β (TGF-β) as an EMT-induction factor induces EMT through a variety of signal pathways as well as the classical TGFβ-Smad pathway. Activated
Smads combine with Smad4 to regulate the transcription of many TGF-β/Smad target genes such as E-cadherin. Smurf1 and Smurf2 target the activated Smads for polyubiquitylation and degradation. 11 Other transcription factors also play a role in EMT, such as Snail, Twist and ZEBs. 12, 13 ZEB expression is induced in response to TGF-β and the induction of ZEB expression is post-transcriptionally repressed by microRNAs (miRNAs). 14 Zeb1 could bind to the E-box elements of E-cadherin promoter and suppress the expression of Ecadherin. 15 However, how the multi-level regulation of EMT in epithelial cells is coordinated remains largely unknown.
In the present study, we aimed at identification of new protein kinases in EMT regulation using the human kinase siRNA library screening in lung cancer cells harboring E-cadherin promoter-reporter construct. We found that the Never in Mitosis A (NIMA)-related kinase-4 (NEK4) was a positive regulator for lung cancer EMT, resulting in an increased potential for cells to migrate and invade. (1:1) medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cell cultures were grown in a humidified incubator at 37°C and 5% CO 2 .
| MATERIALS AND METHODS

| Cell culture
Human
| DNA constructs
To construct E-cadherin promoter-luciferase reporter vector pGL-Ecadherin, we designed the E-cadherin promoter sequence from −1007 to +29 of the transcriptional start point with Kpn1 and Sac1 enzyme sites. The primer sequences were shown in Table S1 . The E-cadherin promoter fragment was obtained by PCR on genomic DNA from the human A549 cell line. The PCR product was cloned into the pGL4.17[luc2/Neo] vector. The E-cadherin promoter fragment was inserted in the upstream of the luc2 gene to regulate its transcription. The control vector pRL-TK harboring Renilla luciferase is purchased from Promega. To establish the NEK4 overexpression system, we constructed pc-NEK4 plasmid. The NEK4 fragment was obtained by PCR on cDNA generated by RT-PCR of the human A549 mRNA. We designed the NEK4 sequence with HindIII and XhoI enzyme sites. The primer sequences were shown in Table S1 .
The PCR product was cloned into the pc-DNA3.1+ vector.
| NEK4 knockdown or overexpression stable cell lines
To knock down NEK4, the human shRNA NEK4 was cloned into Lenti-X ™ shRNA Expression Systems to generate NEK4-shRNA. The shNEK4 sequences were shown in Table S1 . In brief, 293T cells were co-transfected with the lentiviral vectors, packaging plasmid, and envelope plasmid. The cell culture supernatant was collected 24 h after transfection and centrifuged to remove the cell debris.
A549 cells were transduced with shNEK4 lentiviral particles and a negative control shCon for 48 hours and then selected with 2 μg/mL puromycin (Sigma, St Louis, MO, USA) for 1 week.
To construct the NEK4 overexpression stable cell line, A549 cells were transfected with pc-NEK4 plasmid and a negative control pc-DNA3.1+ for 48 hours and then selected with 500 μg/mL G418 (Sigma) for 2 weeks.
| High-throughput siRNA screening against human kinases
The siGENOME Smart Pool siRNA library targeted against 720 human kinases was from Dharmacon (GE, USA), with a mixture of four siRNAs targeting one kinase. Non-silencing control siRNA was obtained from Table S1 . For miRNA detection, the primers were Table S1 . The fold change of relative expression was calculated by the 2 -ΔΔCt method and normalized against the internal standard GAPDH gene or U6.
| Antibodies and western blot analysis
In the study, the antibody sources and dilution were as follows: anti- lysates were resolved on SDS-PAGE gels and transferred to PVDF membranes. Membranes were probed against specific primary antibodies followed by HRP conjugated secondary antibodies, and then visualized using the ECL Western Blotting System (GE Healthcare).
| Migration assay
The effect of NEK4 on migration capacity was assessed using scratch wound assay. A549 cells were seeded into 6-well culture plates and transfected with siNEK4 or siRNA control for 24 hours.
The next day, cells were grown to complete confluence. Subsequently, 3 parallel, linear wounds were produced in each dish with a 10-μL plastic pipette tip. The cells were then cultured with low serum medium contained 1% FBS supplemented with or without TGF-β. Cell migration was then observed by microscope at different time points. The wound area was measured using ImageJ software.
| Transwell assay
For measuring the effect of NEK4 on invasion capacity, transwell invasion assay was performed. A549 cells were transfected with siNEK4 or siRNA control for 24 hours. Then the cells were suspended in serum-free medium and added to the top chamber of the 24-well, matrigel-coated transwell chamber system (Corning). Media with 10% serum was added in the bottom chamber. Cells were incubated for 48 or 72 hours at 37°C before test. And then the membrane was fixed using 4% paraformaldehyde and stained with 0.5% crystal violet. At the end of the assay, cells on the membrane were removed using a cotton swab and the cells below the membrane were observed using a microscope.
| Immunofluorescence
A549 cells were plated on glass cover-slips in 6 well plates and transfected with siRNAs for 48 hours and processed for immunofluorescence. Cells on cover-slips were washed with PBS and fixed in 4% paraformaldehyde (15 min at room temperature). Cover-slips were re-washed 3 times in PBS for 5 minutes and blocked by 5%
BSA in PBS for 1 hour. Antibody was added in PBS containing 0.5%
BSA and incubated for 16 hours at 4°C in humidified chamber.
Cover-slips were washed 3 times in PBS and incubated with fluorescent secondary antibody (Abcam, 1:1000) for 1 hour at room temperature. After washing, cover slips were mounted in DAPI, dried and stored at −20°C until microscopy. Micrographs were taken using Olympus fluorescent microscope.
| Pulmonary metastasis model
The animal experiments were approved by the Animal Ethics Com- 
Immunohistochemistry
For histological examination, the pulmonary tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin, and 4 μm sections were prepared for H&E stain and immunohistological assay.
E-cadherin was detected using an anti-E-cadherin antibody. NEK4
was detected using an anti-NEK4 antibody.
| Statistical analysis
Statistical analyses were performed using GraphPad prism 6.01 software. The data are presented as the means ± SD. The statistical analyses were performed using Student's t test or spearman. The P < 0.05 were considered to be statistically significant.
| RESULTS
| Identification of NEK4 protein kinase as regulator of E-cadherin in A549 cells
To identify potential kinases that are involved in regulation of EMT progress, we utilized a TGF-β-induced EMT model in A549 lung adenocarcinoma cells. After TGF-β treatment for 48 h, the cells exhibited typical EMT morphology ( Figure 1A ). In this model, we performed the siRNA library targeting human kinases (totally 720), according to siRNA effect on E-cadherin promoter activity. Based on the first-round screening, we selected the positive hits for secondround confirmative screening, from which we selected 13 negative candidates and 13 positive candidates according to their consistency between the results from the two rounds (Table S2 and Figure 1B ). 
| The biological function of NEK4 associated with EMT
Although NEK4 has been reported to play some roles in DNA repair and apoptosis, [16] [17] [18] [19] little is known about its effect on cancer cell EMT, which is closely associated with the potential of cancer cell invasion and metastasis. As we observed that NEK4 knockdown induced robust increase of E-cadherin promoter activity and NEK4 expression was up-regulated during the EMT progress, we speculated that NEK4 might mediate cell invasion and metastasis by promoting EMT. To confirm this hypothesis, we investigated the function of NEK4 in matrigel-coated transwell assay and scratch assay. We found that knockdown of NEK4 in A549 cells significantly inhibited cell migration and invasion (Figure 2A-C) . We also found a reduced migratory ability of the cells when treated with siNEK4 in the EMT model of A549 cells induced by TGF-β ( Figure S2 ). Furthermore, we demonstrated that over-expression of NEK4 promoted cell migration and invasion ( Figure 2D-G) . These results suggest that NEK4 is a promotor of cell invasion and migration.
| NEK4 regulation of EMT molecular markers
The 
| NEK4 regulation of EMT-associated transcription factors and signal transduction
As NEK4 was selected based on its impact on E-cadherin promotor activity upon TGF-β treatment, we next examined the effect of NEK4 on the EMT-related transcription factors. Snail and ZEB transcriptional regulators have emerged as key regulatory nodes for EMT. 16 In A549 cells, we found that when NEK4 was inhibited, the expression of ZEB1 was decreased while Snail1 was not affected and Smads ( Figure 4D and E), which was consistent with that in A549 cells.
Considering miR200 family has been suggested to be important regulators of EMT, 14, 17 we also examined the effect of NEK4 on miR200 levels and found no significant changes in A549 cells with NEK4 knockdown ( Figure S4B) . Together, the present data implied that the NEK4 regulated the TGF-β-induced EMT through Smads and ZEB1.
| NEK4 promotion of invasion and migration in vivo
To further verify the function of NEK4 in vivo, we established stable Figure 5F and G). Statistical analysis showed a negative correlation between NEK4 and Ecadherin levels, which showed that the decreased NEK4 expression accompanied with the E-cadherin up-regulation ( Figure 5F and H).
Hence, these results indicated that the knockdown of NEK4 increased the expression of E-cadherin and inhibited the tumor formation in the mice pulmonary. EMT. 24 We propose that NEK4 may mainly contribute to the process of loss of epithelial characteristics.
| DISCUSSION
The EMT progression is regulated at multiple levels, including receptor mediated signal transduction, transcription activation and epigenetic regulation such as miRNAs. Our screening results indicated that NEK4 knockdown led to a higher luciferase activity. This implied that NEK4 could influence the E-cadherin promoter activity either directly or indirectly. By examining two most important EMT transcription factors Snails and ZEBs, we found ZEB1 was the key molecule involved in NEK4-related E-cadherin promoter activity regulation and not regulated by miR200. Further analyzing the involved signal transducers of TGF-β pathways, Smad3 was found to be the most significant effector molecule, although the direct substrates for NEK4 were not identified in the present study. Accordingly, NEK4
may be an important regulator during early phase of EMT via transcriptional activation of an array of EMT-related genes.
In summary, we provided the evidence showing that NEK4 can promote EMT both in vitro and in vivo. Thus, further characterization of NEK4 both biochemically and molecularly in EMT process is warranted.
